Streetbeat News

Products Services

SABS

SABSW

SAB Biotherapeutics has announced a private placement of up to $130 million to advance the development of its lead drug candidate for Type 1 Diabetes.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:15 am

RCKT

The FDA has accepted Rocket Pharmaceuticals' Biologics License Application and granted priority review for RP-L201 gene therapy for severe leukocyte adhesion deficiency-I. The PDUFA date is set for March 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:13 am

CSTL

Castle Biosciences has announced new data demonstrating the significant clinical utility of its TissueCypher Barrett's Esophagus Test for patients with non-dysplastic Barrett's Esophagus at a higher risk of progression to high-grade dysplasia or esophageal adenocarcinoma.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:11 am

SNDX

Syndax's AUGMENT-101 trial of Revumenib in relapsed/refractory KMT2Ar Acute Leukemia has met its primary endpoint and has been stopped early due to efficacy following a protocol-defined interim analysis.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:08 am

DNA

Nosh.bio has partnered with Ginkgo Bioworks to enhance the meaty taste of its mycoprotein products. The partnership will leverage Ginkgo's strain optimization services to improve the flavor profile of Nosh.bio's products.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:07 am

TRVN

Trevena, Inc. (NASDAQ:TRVN) has completed the initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study. The study assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:07 am

CGEN

Compugen announced that the Japanese Patent Office has granted a patent for treating cancer with a triple combination of any anti-PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody. This strengthens Compugen's patent portfolio and leadership in blocking three pathways of the DNAM-1 axis.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:04 am

ACXP

Acurx Pharmaceuticals has successfully completed and prematurely discontinued the Ibezapolstat Phase 2b trial for the treatment of C. difficile infection.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:03 am

APLS

Apellis Pharmaceuticals has received US FDA approval for its EMPAVELI Injector, a device designed to streamline self-administration of EMPAVELI (pegcetacoplan), a treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH).

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:02 am

CABA

Cabaletta Bio has received FDA clearance for its Investigational New Drug (IND) application for CABA-201, a treatment for systemic sclerosis. This approval allows the company to proceed with clinical trials.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:01 am